Pfenex

109 articles with Pfenex

• 

  Ligand Buys Pfenex in $516 Million Deal to Access Protein Production Platform

  8/11/2020

  Pfenex’ proprietary protein production platform, Pfenex Expression Technology, is used to improve existing treatments and create novel therapies.
• 

  Clinical Catch-Up: October 14-18

  10/21/2019

  Last week was busy for clinical trial news. Here’s a look.
• 

  FDA Action Alert: PFEnex, Flexion, Alexion and Clearside

  10/7/2019

  There are several scheduled PDFUA dates for the U.S. Food and Drug Administration over the next two weeks. Here’s a look.
• 

  Movers and Shakers for Sept. 10

  9/10/2018

  Let's take a look at who made a splash in the pharma and biotech world the past week.

• Pfenex to Report First Quarter 2018 Results and Provide Business Update on Thursday, May 10th

  4/30/2018

  Pfenex Inc. announced that its first quarter 2018 financial results will be released on Thursday, May 10, 2018.

• Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo®

  4/18/2018

  Pfenex Inc. and China NT Pharma Group Company Limited announced an agreement under which Pfenex granted NT Pharma non-exclusive development and exclusive commercialization rights to PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly & Company's Forteo®, in Mainland China, Hong Kong, Singapore, Malaysia and Thailand.

• 

  Drugs That Are Likely to Fall Off the Patent Cliff This Year

  4/5/2018

  If a brand name drug loses patent protection, that often marks the date when companies can begin marketing generic versions of the drug. However, this has grown more complicated with the approvals of biosimilars.

• Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update

  3/15/2018

  Pfenex Inc. reported financial results for the fourth quarter and full year ended December 31, 2017 and provided a business update.

• Pfenex Names Susan A. Knudson as CFO

  1/4/2018

  Pfenex today announced the appointment of Susan A. Knudson as CFO, effective February 1, 2018.

• Pfenex Earns $18.5M in Milestones and Updates Worldwide License and Option Agreement With Jazz Pharma

  12/19/2017

  Pfenex today announced the amendment of the 2016 agreement under which Pfenex granted Jazz Pharma worldwide rights to develop and commercialize multiple early stage hematology product candidates.

• Pfenex Reports Third Quarter 2017 Results, Interim PK Data From PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update

  11/10/2017

  Using the patented Pfenex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars.

• Pfenex to Report Third Quarter 2017 Results and Provide Business Update on Thursday, November 9, 2017

  10/31/2017

  Pfenex announced today that its third quarter 2017 financial results will be released on Thursday, November 9, 2017, after the market close.

• San Diego's Pfenex CFO And Chief Manufacturing Officer To Exit

  9/8/2017

• Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules

  9/1/2017

• Pfenex Reports Second Quarter 2017 Results And Provides Business Update

  8/10/2017

• Former Alvotech Exec Jumps Ship to Pfenex as CEO

  8/3/2017

• Pfenex To Report Second Quarter 2017 Results and Provide Business Update on Wednesday, August 9, 2017

  7/26/2017

• Pfenex Reports First Quarter 2017 Results and Provides Business Update

  5/9/2017

• Pfenex To Report First Quarter 2017 Results And Provide Business Update On Monday, May 8, 2017

  4/24/2017

• Pfenex Release: William R. Rohn Announces Plans To Retire As Chairman And Board Member

  4/3/2017